Maplight Therapeutics Common Stock Analysis
| MPLT Stock | 16.98 1.28 8.15% |
At this time, MapLight Therapeutics' Net Debt To EBITDA is comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.1 in 2026, whereas Total Debt To Capitalization is likely to drop 0.06 in 2026. MapLight Therapeutics' financial risk is the risk to MapLight Therapeutics stockholders that is caused by an increase in debt.
Given that MapLight Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which MapLight Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of MapLight Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, MapLight Therapeutics is said to be less leveraged. If creditors hold a majority of MapLight Therapeutics' assets, the Company is said to be highly leveraged.
Enterprise Value is likely to drop to about 789.3 M in 2026. MapLight Therapeutics Common is overvalued with Real Value of 14.16 and Hype Value of 16.56. The main objective of MapLight Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what MapLight Therapeutics Common is worth, separate from its market price. There are two main types of MapLight Therapeutics' stock analysis: fundamental analysis and technical analysis.
The MapLight Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. MapLight Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. MapLight Stock trading window is adjusted to America/New York timezone.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MapLight Therapeutics Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. MapLight Stock Analysis Notes
The company had not issued any dividends in recent years. To find out more about MapLight Therapeutics Common contact the company at 617 984 6300 or learn more at https://www.maplightrx.com.MapLight Therapeutics Investment Alerts
| MapLight Therapeutics had very high historical volatility over the last 90 days | |
| MapLight Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Insider Selling Maplight Therapeutics Director Sells 7,0 Shares of Stock |
MapLight Largest EPS Surprises
Earnings surprises can significantly impact MapLight Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-12-04 | 2025-09-30 | -1.72 | -37.18 | -35.46 | 2061 |
MapLight Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.61) | (0.64) |
Technical Drivers
As of the 10th of February, MapLight Therapeutics secures the Downside Deviation of 4.13, mean deviation of 4.01, and Risk Adjusted Performance of 0.0311. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MapLight Therapeutics, as well as the relationship between them.MapLight Therapeutics Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in MapLight Therapeutics price series with the more recent values given greater weights.
MapLight Therapeutics Outstanding Bonds
MapLight Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MapLight Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MapLight bonds can be classified according to their maturity, which is the date when MapLight Therapeutics Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MapLight Therapeutics Predictive Daily Indicators
MapLight Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MapLight Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MapLight Therapeutics Forecast Models
MapLight Therapeutics' time-series forecasting models are one of many MapLight Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MapLight Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.MapLight Therapeutics Bond Ratings
MapLight Therapeutics Common financial ratings play a critical role in determining how much MapLight Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for MapLight Therapeutics' borrowing costs.MapLight Therapeutics Ptb Ratio Over Time
MapLight Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which MapLight Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.MapLight Therapeutics Debt Ratio | 9.98 |
MapLight Therapeutics Corporate Bonds Issued
MapLight Net Debt To E B I T D A
Net Debt To E B I T D A |
|
About MapLight Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how MapLight Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MapLight shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as MapLight Therapeutics. By using and applying MapLight Stock analysis, traders can create a robust methodology for identifying MapLight entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding MapLight Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Additional Tools for MapLight Stock Analysis
When running MapLight Therapeutics' price analysis, check to measure MapLight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MapLight Therapeutics is operating at the current time. Most of MapLight Therapeutics' value examination focuses on studying past and present price action to predict the probability of MapLight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MapLight Therapeutics' price. Additionally, you may evaluate how the addition of MapLight Therapeutics to your portfolios can decrease your overall portfolio volatility.